These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 22421927)

  • 1. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
    O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
    Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.
    Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S
    Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders.
    Pi-Sunyer X; Shanahan W; Fain R; Ma T; Garvey WT
    Postgrad Med; 2016 Aug; 128(6):591-7. PubMed ID: 27389084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Bohula EA; Scirica BM; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Kanevsky E; Murphy SA; Leiter LA; Dwyer JP; Corbalan R; Hamm C; Kaplan L; Nicolau JC; Ophuis TO; Ray KK; Ruda M; Spinar J; Patel T; Miao W; Perdomo C; Francis B; Dhadda S; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
    Lancet; 2018 Nov; 392(10161):2269-2279. PubMed ID: 30293771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
    Lewin A; Lipetz R; Wu J; Schwartz S
    Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
    Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus.
    Magkos F; Nikonova E; Fain R; Zhou S; Ma T; Shanahan W
    Obesity (Silver Spring); 2017 May; 25(5):842-849. PubMed ID: 28345809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss.
    Handelsman Y; Fain R; Wang Z; Li X; Fujioka K; Shanahan W
    Postgrad Med; 2016 Nov; 128(8):740-746. PubMed ID: 27659698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
    Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
    Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes.
    Smith SR; O'Neil PM; Astrup A; Finer N; Sanchez-Kam M; Fraher K; Fain R; Shanahan WR
    Obesity (Silver Spring); 2014 Oct; 22(10):2137-46. PubMed ID: 25044799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
    Bohula EA; Wiviott SD; McGuire DK; Inzucchi SE; Kuder J; Im K; Fanola CL; Qamar A; Brown C; Budaj A; Garcia-Castillo A; Gupta M; Leiter LA; Weissman NJ; White HD; Patel T; Francis B; Miao W; Perdomo C; Dhadda S; Bonaca MP; Ruff CT; Keech AC; Smith SR; Sabatine MS; Scirica BM;
    N Engl J Med; 2018 Sep; 379(12):1107-1117. PubMed ID: 30145941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
    Smith SR; Prosser WA; Donahue DJ; Morgan ME; Anderson CM; Shanahan WR;
    Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
    Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
    Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia.
    Nesto R; Fain R; Li Y; Shanahan W
    Postgrad Med; 2016 May; 128(4):364-70. PubMed ID: 27116910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
    Hollander P; Lasko B; Barnett AH; Bengus M; Kanitra L; Pi-Sunyer FX; Balena R
    Obesity (Silver Spring); 2013 Feb; 21(2):238-47. PubMed ID: 23404788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.